HC Wainwright & Co. reiterates Buy rating on Acurx Pharmaceuticals, $31 price target

HC Wainwright & Co. reiterated their Buy rating on Acurx Pharmaceuticals's stock with a price target of $31.00.The price target implies an upside of 2213.4% from the Sep 28 close of $1.34.Key takeaways from the analyst notePositive FDA Engagement: Acurx Pharmaceuticals has received favorable feedba…